PSMA-targeted radioligand for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and are at least 18 years old.
- You have confirmed prostate cancer that has spread to bone or lymph nodes, and your PSA is rising.
- Your general health is fair enough to do study activities (ECOG 0–2).
- Your cancer has progressed after prior treatments, including taxane chemotherapy and at least one AR-targeted hormone medicine (like enzalutamide or abiraterone), unless you couldn’t take them.
- A scan shows your tumors strongly “light up” on PSMA PET/CT (PSMA uptake thresholds), and you’re continuing hormone suppression with low testosterone.
- You must have enough blood counts and organ function (bone marrow, liver, and kidneys) and an estimated life expectancy of 6 months or more.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This Phase 1/2 trial tests a personalized form of PSMA-targeted radiation therapy for adults with advanced cancers that strongly show PSMA on a PET scan. It may help shrink or control tumors by delivering radiation directly to PSMA-expressing cancer cells.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.